



EQUASENS : IMPLEMENTATION OF A LIQUIDITY CONTRACT WITH NATIXIS ODDO BHF

Villers-lès-Nancy, April 1, 2026, 6 :00 pm CEST – Equasens (isin : FR0012882389 – Ticker : EQS), a leader in digital solutions for healthcare professionals, announces the termination of the liquidity contract with Gilbert Dupont, which had been in effect since May 2, 2005.

As of April 1, 2026, and for a renewable period of one year subject to automatic renewal, the Company has entrusted Natixis Oddo BHF with the implementation of a liquidity and market surveillance agreement covering its ordinary shares.

This contract complies with the decision of the Autorité des marchés financiers (AMF) n°2021-01 of June 22, 2021 related to the establishing of liquidity contracts on shares as accepted market practice and the standard contract of the Association Française des Marchés Financiers (AMAFI).

This contract with NATIXIS ODDO BHF aims at improving Company’s shares trading on the regulated market of Euronext Paris

It is recalled that, upon the establishment of the initial contract with Gilbert Dupont, the following resources were allocated to the liquidity account:

- **2 219 Equasens shares**
- **50 000,00 €**

At the time of the last half-yearly statement as of December 31, 2025, the following resources were recorded in the liquidity account:

- **2 501 Equasens shares**
- **Cash balance: 103 028,03 €**

As of the termination date of the previous contract, March 31, 2026, the following resources were recorded in the liquidity account:

- **Number of shares: 2 153**
- **Cash balance: 164 707,79 €**

The resources allocated to the implementation of the new contract are:

- **Number of shares: 2 153**
- **413 664.07 €**

The execution of the liquidity contract may be suspended upon occurrence of the following events or conditions:

- when all conditions provided in Article 5 of the AMF Decision n°2021-01 June 22, 2021 are met;
- if the share is listed outside the thresholds authorized by the Company's Shareholders' Meeting;
- upon the Company request.

The liquidity contract may be terminated at any time and without prior notice by Equasens, at any time by NATIXIS and/or ODDO BHF SCA subject to fifteen (15) calendar days' notice

Equasens Groupe

Founded over 35 years ago, Equasens Group, a leader in digital healthcare solutions, today employs over 1,500 people across Europe.

Equasens Group's specialised business applications facilitate the day-to-day work of healthcare professionals and their teams, working in private practice, collaborative medical structures or healthcare establishments. The Group also provides comprehensive support to healthcare professionals in the transformation of their profession by developing electronic equipment, digital solutions and healthcare robotics, as well as data hosting, financing and training adapted to their specific needs.

And reflecting the spirit of its tagline "Technology for a More Human Experience", the Group is a leading provider of interoperability solutions that improve coordination between healthcare professionals, their communications and data exchange resulting in better patient care and a more efficient and secure healthcare system.

Financial calendar –2026 Q1 revenue : April 29, 2026 (after market close)

Listed on Euronext Paris™ - Compartment B Indices : MSCI GLOBAL SMALL CAP - GAÏA Index 2020 - CAC® SMALL et CAC® All-Tradable.

Included in the Euronext Tech Leaders segment and the European Rising Tech table.

Eligible for the Deferred Settlement Service ("Service à Règlement Différé" - SRD) and equity savings accounts invested in small and mid caps (PEA-PME).

Get all the news about Equasens Group on www.equasens.com and on [LinkedIn](#).

Investor Relations and Media Contacts

Groupe Equasens

Investor Relations

CFO

Frédérique Schmidt

Tel. : +33 (0)3 83 15 90 67

frederique.schmidt@equasens.com

NewCap

Investor Relations

Thomas Grojean

Louis-Victor Delouvrier

Tel : +33 (0)1 44 71 94 94

equasens@newcap.eu

NewCap

Financial Media Relations

Nicolas Mériageau

Tel : +33 (0)1 44 71 94 94

equasens@newcap.eu